Hormonal Disorders

Jul 29, 2024 | academic.oup.com | Hormonal Disorders

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from the parafollicular C cells of the thyroid and represents only 1% to 2% of all thyroid cancers [1]. Up to 20% of patients present with distant metastases, most commonly in the lungs, liver, and bones [2, 3]. Although many patients can have an indolent course despite distant disease, the 10-year survival from time of first metastasis is 10% to 40% [1].

Jul 11, 2024 | jamanetwork.com | Sarah Hamidi |Hormonal Disorders |Mark E. Zafereo |Jennifer Wang

Abstract Importance  BRAF/MEK inhibitors revolutionized the treatment of BRAF V600E-variant anaplastic thyroid carcinoma (BRAFv-ATC), offering improved outcomes for patients with this previously incurable disease. Observations  Anaplastic thyroid carcinoma (ATC) accounts for approximately half of thyroid cancer−related deaths.

May 6, 2024 | jamanetwork.com | Laura Boucai |Mark E. Zafereo |Maria E Cabanillas |Hormonal Disorders

A Review of Thyroid Cancer—Reply In Reply We appreciate letters about our Review on thyroid cancer.1 In response to the comments by Drs Beheshtirouy and Shayanfar, the causal association between GLP-1 RA use and thyroid cancer is complex and requires careful consideration of factors that directly or indirectly influence carcinogenesis pathways such as the direct biological effects of the drug, host susceptibility factors (eg, obesity or proinflammatory states), biases embedded in clinical...

Apr 9, 2024 | thelancet.com | Matthew Campbell |Vania Balderrama-Brondani |Hormonal Disorders |Camilo Jimenez

Summary Adrenocortical carcinoma is a rare malignancy with poor response to systemic chemotherapy. Mitotane is the only approved therapy for adrenocortical carcinoma. Cabozantinib is a multikinase inhibitor approved in multiple malignancies. This is the first prospective trial to explore the anti-tumour activity, safety, and pharmacokinetic profile of cabozantinib in patients with advanced adrenocortical carcinoma.

Feb 6, 2024 | jamanetwork.com | Laura Boucai |Mark E. Zafereo |Maria E Cabanillas |Hormonal Disorders

Thyroid Cancer: A Review US Preventive Services Task Force USPSTF Recommendation: Screening for Thyroid Cancer US Preventive Services Task Force; Kirsten Bibbins-Domingo, PhD, MD, MAS; David C. Grossman, MD, MPH; Susan J. Curry, PhD; Michael J. Barry, MD; Karina W. Davidson, PhD, MASc; Chyke A. Doubeni, MD, MPH; John W. Epling Jr, MD, MSEd; Alex R. Kemper, MD, MPH, MS; Alex H. Krist, MD, MPH; Ann E. Kurth, PhD, RN, MSN, MPH; C. Seth Landefeld, MD; Carol M.